NEXTDC (ASX:NXT) Record 667MW Contracted & A$2.2B Capital Plan
S4 hits 71% contracted as utilisation jumps 60% to 667MW
NextDC (ASX:NXT) has added 250MW…
- ASX: IMC
Immuron Ltd
Share Price and News
ASX BIG FOUR - LIVE SNAPSHOT
SELL
Whitehaven Coal
(ASX:WHC)
Paul Flynn
01/03/2026
$8.7m
BUY
Elixir Energy
(ASX:EXR)
Featured
SELL
Aspen Group
(ASX:APZ)
David Dixon
03/03/2026
$11.4m
BUY
Lovisa
(ASX:LOV)
Brett Blundy
04/03/2026
$6.8m
— Copmany Overview
Introduction to Immuron
Immuron ( NASDAQ: IMRN, ASX: IMC) is an Australia n biotech company developing commercial assets that help transform the standard of care for gastrointestinal disorders. IMC has 2 flagship commercial products – Travelan and Protectyn – and 3 clinical-stage assets – IMM-529, IMM-124E and CampETEC.
Travelan and Protectyn are oral immunotherapeutic products. The former helps reduce the risk of traveller’s diarrhoea (TD), while the latter is a dietary supplement for gut health that has been formulated to help maintain a healthy digestive function and support the liver.
Both are likely to remain attractive amid concerns related to antibiotic resistance. Immuron’s sales have increased in recent years from <$1m in FY22 to $7.3m within 3 years. Immuron is also developing clinical stage assets that offer further upside potential for investors.
Immuron's Company History
Immuron is an Australian biopharmaceutical company with a long-standing focus on gastrointestinal and infectious disease therapeutics. It is dual-listed on the ASX (as IMC) and on NASDAQ (as IMRN), giving it access to both Australian and US investors. The company’s commercial portfolio has been anchored by its Travelan product, used for the prevention of travellers’ diarrhoea, alongside an ongoing clinical pipeline focused on related indications.
- Free Report
Get Our Full ASX Stock Analysis Report
Expert buy ranges, stop losses and detailed fundamentals for 200+ ASX stocks – free every week.
— Forward View
Future Outlook of Immuron (ASX: IMC)
IMM-124E i s th e drug substance and the active pharmaceutical ingredient in Travelan. In the U.S., Travelan ® is marketed as a dietary supplement for digestive tract protection and as such the company cannot make any claims about the therapeutic benefits against Travel l ers’ diarrhoea. But the company is pursuing a regulatory pathway to license Travelan against trave l lers’ diarrh o ea ( Travelan Rx), an indication for which there are no FDA approved drug s for. IMC is conducting a Phase 2 clinical trial in the US with IMM-124E and interim data has been very promising. The company is planning to take it to Phase 3 within the next 12 months. As for IMM-529 and CampETEC, these are oral formulation s intended for patients suffering from recurring Clostridioides D i fficile infection and moderate to severe campylobacteriosis respectively. Shareholders can look forward to continued progress with these assets too. Their strategic positioning in the biopharmaceutical sector, combined with positive travel statistics and a successful Amazon launch, paints an optimistic picture for their continued growth and market expansion.
— Our Assessment
Is Immuron (ASX: IMC) a Good Stock to Buy?
Immuron Limited emerges as an attractive investment prospect. There are few companies that have both commercial assets with surging sales and clinical stage assets with significant upside. The company riding the wave of a significant sales surge in its flagship product, Travelan®. There is also upside as the company pursues its clinical ambitions, particularly with IMM-124E. By early 2025, it could well be one of only a handful of ASX biotech stocks with an asset in a Phase 3 trial.
— Our Stock Analysis
Related Articles
TSMC’s (NSDQ:TSM) Money Printer, March Revenue $13.1B, Margins Hit 58%
Record Margins, AI Demand Still Accelerating
TSMC (NSDQ:TSM) continues to show real pricing power. Demand…
ASML (NASDAQ:ASML) Q1 sales +15%, but system shipments slowed and stock fell 7%
Net orders beat revenue 1.2x, yet investors punished machine sales
ASML (NASDAQ:ASML) sits at the…
Michael Hill (ASX:MHJ): This Under Pressure Jewellery Outlet Is Trying To Position Itself As An AI P...
In this era, every company is trying to position itself as an AI play -…
Here are 5 Recent AI Acquisitions on the ASX! But Are They Just Hype?
This article explores 5 Recent AI Acquisitions on the ASX and whether or not these…
Amazon Is Making Returns from AI – A Whopping US$15bn In Just One Quarter!
It is that time of year again when Amazon releases its annual shareholder letter (along…
— Faq
Frequently Asked Questions
What is Immuron's main product?
Immuron’s flagship product is Travelan®, an over-the-counter supplement designed to combat traveler’s diarrhea and promote digestive health. Travelan® is clinically proven to reduce gastrointestinal disorders, particularly beneficial for travelers and those with sensitive digestive systems.
How has Immuron performed recently?
Immuron has experienced a significant surge in sales recently. Travelan® sales increased by 49% in FY25 to reach A$7.3m.
Where is Immuron listed?
Immuron is dual-listed, trading on the Australian Securities Exchange under the ticker IMC and on the NASDAQ under the ticker IMRN. This dual-listing structure gives the company exposure to both Australian and US investor bases.
Does Immuron pay dividends?
Immuron does not currently pay dividends. Available capital is directed toward scaling the company’s commercial products and funding clinical-stage assets in its pipeline rather than shareholder distributions.
What are the main risks of investing in Immuron?
Key risks include commercial execution on Travelan sales, clinical trial outcomes for pipeline assets, competition in the gastrointestinal health category, foreign exchange exposure given the company’s US market activities, and the possibility that further capital may be required to support growth initiatives.
Stay Sharp on the ASX
Weekly research. Independent analysis. No noise.
Free forever · Unsubscribe anytime
